Results 101 to 110 of about 2,242,189 (260)

Efficacy and related factors of levonorgestrel‐releasing intrauterine system combined with metformin in fertility‐preserving treatment for atypical endometrial hyperplasia and early endometrial cancer: A retrospective cohort study

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To compare the efficacy of the levonorgestrel‐releasing intrauterine system combined with metformin versus oral progestin combined with metformin in fertility‐preserving treatment for patients with atypical endometrial hyperplasia and early endometrial cancer, and to analyze related factors affecting efficacy.
Pengpeng Gu, Jialu Gao, Yuxin Li, Mei Huang, Xiaoshuang Wang, Xin Zhao   +5 more
wiley   +1 more source

Tamoxifen resistance and adjuvant hormone therapy [PDF]

Breast Cancer Research, 2005
The Oxford Overview of adjuvant endocrine trials [1] indicates that 5 years of adjuvant tamoxifen reduces recurrence by 41% and deaths by 34% in women with oestrogen receptor (ER)-positive breast cancers. At 5 years, in all patients studied, the recurrence rate was 25.8% in controls but 13.9% on tamoxifen. There was a substantial 'carry over' effect of
openaire   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity

Cell Reports, 2015
Breast cancers (BCs) typically express estrogen receptors (ERs) but frequently exhibit de novo or acquired resistance to hormonal therapies. Here, we show that short-term treatment with the anti-estrogens tamoxifen or fulvestrant decrease cell ...
Bruno M. Simões, Ciara S. O’Brien, Rachel Eyre, Andreia Silva, Ling Yu, Aida Sarmiento-Castro, Denis G. Alférez, Kath Spence, Angélica Santiago-Gómez, Francesca Chemi, Ahmet Acar, Ashu Gandhi, Anthony Howell, Keith Brennan, Lisa Rydén, Stefania Catalano, Sebastiano Andó, Julia Gee, Ahmet Ucar, Andrew H. Sims, Elisabetta Marangoni, Gillian Farnie, Göran Landberg, Sacha J. Howell, Robert B. Clarke   +24 more
doaj   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

Targeting lipid metabolism to overcome tamoxifen resistance in breast cancer: Evaluating the synergistic therapeutic potential of quercetin

Cancer Treatment and Research Communications
Breast cancer remains the most prevalent malignancy among women globally, with hormone receptor-positive subtypes representing the majority of cases. Despite significant advances in treatment, resistance to Tamoxifen, a cornerstone therapy for estrogen ...
Radwa M. Rifaat, Marwa W. Kamel, Marwa Sharaky, Yasmin M. Attia, Samia A. Shouman   +4 more
doaj   +1 more source

Microbial metabolite indole‐3‐propionic acid preserves astrocytic mitochondrial mitofusin 2 to limit neuroinflammation after traumatic brain injury

Interdisciplinary Medicine, EarlyView.
Following traumatic brain injury, indole‐3‐propionic acid (IPA) directly targets the aryl hydrocarbon receptor on astrocytes in the peri‐lesional cortex; this suppresses interferon regulatory factor 1‐driven transcription of the E3 ubiquitin ligase RFFL (ring finger and FYVE‐like domain containing E3 ubiquitin protein ligase).
Ziwen Zhang, Kai Wang, Liangbo Wang, Wencong Li, Hao Guo, Meng Xu, Tinghao Wang, Jiahui Ren, Ting Zhu, Jiahui Wang, Wenxing Cui, Jinpeng Zhou, Yang Tian, Liying Han, Chengxuan Guo, Shuoyao Ma, Qiang Wang, Zhihong Li, Yaning Cai, Jingyu Dong, Xun Wu, Haixiao Liu, Yan Qu   +22 more
wiley   +1 more source

Drug resistance to tamoxifen: mutant estrogen receptors as a potential mechanism of tamoxifen-stimulated tumor growth

, 1995
INTRODUCTION Tamoxifen is the endocrine treatment of choice for all stages of breast cancer (Jordan 1993). The adjuvant use of tamoxifen produces survival advantages and prevents the appearance of a second primary
V C Jordan, W L Catherino, D M Wolf
core   +1 more source

Mitochondria‐targeted nanomedicine for cancer therapy: Targeting strategies, therapeutic mechanisms, and translational challenges

Interdisciplinary Medicine, EarlyView.
This review highlights recent advances in mitochondria‐targeted nanomedicine for cancer therapy. It summarizes key targeting strategies and delineates four principal therapeutic mechanisms: oxidative stress–induced mitochondrial dysfunction, disruption of energy metabolism, direct mitochondrial damage, and induction of immunogenic cell death.
Linfeng Xiao, Xiaowei Chang, Jun Zhang, Yinshan Hong, Wenhui Cao, Zhewu Zhao, Yu‐E. Wang, Yanling Yang   +7 more
wiley   +1 more source

Kurkumin Meningkatkan Sensitivitas Sel Kanker Payudara terhadap Tamoksifen Melalui Penghambatan Ekspresi P-glikoprotein dan Breast Cancer Resistance Protein

Jurnal Farmasi Galenika (Galenika Journal of Pharmacy), 2018
The decreasing of sensitivity or resistance to tamoxifen occured after long-term treatment in breast cancer. One of the major factor in tamoxifen resistance is over expression of efflux transporter P-glycoprotein (P-gp) and Breast Cancer Resistance ...
Erlia Anggrainy Sianipar, Melva Louisa, Septelia Inawati Wanandi   +2 more
doaj   +1 more source